PreComb recognised for healthcare innovation by Sustainable Times RISE Awards

Jens high res

Pioneering biotech company, PreComb, has seen success at the inaugural Sustainable Times RISE Awards after being crowned the winner of the Sustainable Startups in Healthcare category.

 

Celebrating the future of sustainable innovation, the RISE awards honour the bold innovators and businesses tackling the most pressing environmental and social challenges of today. The winners were announced on 6 November at London’s Grand Connaught Rooms, where leaders and changemakers from across the sustainability sector came together to honour outstanding achievements in sustainable innovation.

 

PreComb impressed the panel of judges for the healthcare category, which showcases health-focused start-ups using technology and investment to improve patient care, accessibility and sustainability in healthcare.

 

Established in 2018 by three accomplished serial medical entrepreneurs, PreComb is underpinned by its core mission to accelerate oncology drug development by creating predictive, physiologically relevant tumour models and workflow technologies that mirror human biology more closely than traditional 2D or simple in vivo models.

 

Now entering its Series B funding round, the advanced biotech company is in the process of building a fully automated, on-site platform to test drug response on patient-derived 3D micro tumours.

 

By bringing high-throughput functional profiling into clinical environments, the technology aims to let institutions routinely test curated portfolios of cancer drugs and combinations — supporting pharma R&D and, pending regulatory approvals, helping to drive effective clinical decision-making.

 

Jens Kelm, Co-Founder and CSO of PreComb said: “This award is a huge achievement for us at PreComb and is testament to the hard work and passion our team puts in every day to accelerate drug development and transform precision oncology.

 

“Our ultimate aim is to improve patient outcomes and reduce cancer-related deaths worldwide with the development of our 3DTwin® technology and real-time profiling. By replicating each patient’s unique tumor drug-response dynamics in an ex vivo setting, we generate more reliable data to guide therapy selection and improve the likelihood of success in clinical trials. This award is a tremendous vote of confidence in our approach, and we’re deeply grateful for the recognition.”

 

This awards success follows PreComb’s recent collaboration with University Hospital of Zurich, where both parties are working together to explore the potential of the LiveBank platform for pan-cancer drug discovery and development. This includes leveraging real-time patient-derived 3D cancer cell models to identify and profile novel therapeutic strategies across a broad range of tumour types.

 

For more information, visit: https://www.precomb.com